[Correspondence] A new generation of comprehensive precision oncology trials

Ian F Tannock’s Comment1 summarises the experience to date in precision medicine for children with cancer2–4 and its parallel with the adult experience. The author states that we should not initiate large trials of precision cancer therapy until further progress in our understanding of paediatric cancer unveils new therapeutic strategies that might improve patient outcomes.